Sichuan Biokin - Public Comps and Valuation Multiples

Sichuan Biokin Overview

About Sichuan Biokin

Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.

Founded

2006

HQ

Employees

n/a

Website

en.baili-pharm.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $316M

Last FY EBITDA $586M

EV

$18.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sichuan Biokin Financials

As of December 2025, Sichuan Biokin reported last 12-month revenue of $316M.

In the same period, Sichuan Biokin generated $283M in LTM gross profit and -$66.4M in net income.

See Sichuan Biokin valuation multiples based on analyst estimates

Sichuan Biokin P&L

In the most recent fiscal year, Sichuan Biokin reported revenue of $832M and EBITDA of $586M.

Sichuan Biokin expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sichuan Biokin valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$316M	XXX	$832M	XXX	XXX	XXX
Gross Profit	$283M	XXX	$794M	XXX	XXX	XXX
Gross Margin	90%	XXX	95%	XXX	XXX	XXX
EBITDA	n/a	XXX	$586M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	70%	XXX	XXX	XXX
EBIT	-$68.6M	XXX	$535M	XXX	XXX	XXX
EBIT Margin	-22%	XXX	64%	XXX	XXX	XXX
Net Profit	-$66.4M	XXX	$530M	XXX	XXX	XXX
Net Margin	-21%	XXX	64%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sichuan Biokin including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $316M. In the most recent fiscal year, Sichuan Biokin achieved $832M in revenue and $586M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$316M	Analyst estimates available to subscribers	$832M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$283M	Analyst estimates available to subscribers	$794M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	89.6% gross margin	Analyst estimates available to subscribers	95.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$586M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	70.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$68.6M	Analyst estimates available to subscribers	$535M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-21.7% EBIT margin	Analyst estimates available to subscribers	64.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$66.4M	Analyst estimates available to subscribers	$530M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-21.0% net profit margin	Analyst estimates available to subscribers	63.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sichuan Biokin

This financial data table provides comprehensive performance metrics for Sichuan Biokin, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sichuan Biokin generated $316M in revenue over the last twelve months.
Gross profit for the last twelve months was $283M.
Net income over the last twelve months reached -$66.4M.

Fiscal Year Performance

In the most recent fiscal year, Sichuan Biokin reported $832M in total revenue.
Fiscal year EBITDA was $586M.
The company maintained a gross profit margin of 95.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 70.4%.
Net profit margin reached 63.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sichuan Biokin. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sichuan Biokin Stock Performance

Sichuan Biokin has current market cap of CNY 130B (or $18.6B), and EV of CNY 128B (or $18.3B).

Market Cap Evolution

Sichuan Biokin Stock Data

As of January 16, 2026, Sichuan Biokin's stock price is CNY 315 (or $45).

See Sichuan Biokin trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$18.3B	$18.6B	XXX	XXX	XXX	XXX	$-0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sichuan Biokin Valuation Multiples

Sichuan Biokin's trades at 57.7x EV/Revenue multiple, and 31.2x EV/EBITDA.

See valuation multiples for Sichuan Biokin and 15K+ public comps

Sichuan Biokin Financial Valuation Multiples

As of January 16, 2026, Sichuan Biokin has market cap of $18.6B and EV of $18.3B.

Equity research analysts estimate Sichuan Biokin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sichuan Biokin has a P/E ratio of -279.8x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$18.6B	XXX	$18.6B	XXX	XXX	XXX
EV (current)	$18.3B	XXX	$18.3B	XXX	XXX	XXX
EV/Revenue	57.7x	XXX	57.7x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	31.2x	XXX	XXX	XXX
EV/EBIT	-266.1x	XXX	-266.1x	XXX	XXX	XXX
EV/Gross Profit	64.4x	XXX	n/a	XXX	XXX	XXX
P/E	-279.8x	XXX	-279.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	32.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sichuan Biokin Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sichuan Biokin Margins & Growth Rates

Sichuan Biokin's last 12 month revenue growth is 15%

Sichuan Biokin's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Sichuan Biokin's rule of 40 is -106% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sichuan Biokin's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sichuan Biokin and other 15K+ public comps

Sichuan Biokin Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	15%	XXX	3%	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	-106%	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	25%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	31%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial